Cheri Frederick
Psychiatric/Mental Health · Elizabethtown, KYNPI 1548868268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 473 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 9.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 473 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$633
- Otsuka America Pharmaceutical, Inc.$589
- AbbVie$583
- Corium, LLC$574
- Sunovion Pharmaceuticals Inc.$564
- Vanda Pharmaceuticals Inc.$515
- plus $3K from 18 others
What the payments were for
- Food & beverage$6,931100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 50 | $633 |
| Otsuka America Pharmaceutical, Inc. | 41 | $589 |
| AbbVie | 53 | $583 |
| Corium, LLC | 39 | $574 |
| Sunovion Pharmaceuticals Inc. | 46 | $564 |
| Vanda Pharmaceuticals Inc. | 26 | $515 |
| Alkermes, Inc. | 28 | $515 |
| Teva Pharmaceuticals USA, Inc. | 28 | $419 |
| Neurocrine Biosciences, Inc. | 25 | $414 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $389 |
| Axsome Therapeutics, Inc. | 13 | $265 |
| Supernus Pharmaceuticals, Inc. | 24 | $256 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $228 |
| Indivior Inc. | 12 | $219 |
| Johnson & Johnson | 9 | $215 |
| Ironshore Pharmaceuticals Inc. | 9 | $143 |
| E.r. Squibb & Sons, L.L.C. | 6 | $117 |
| Braeburn Inc. | 5 | $93 |
| Collegium Pharmaceutical, Inc. | 3 | $63 |
| Biogen | 3 | $52 |
| Tris Pharma Inc | 3 | $51 |
| USWM, LLC | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$114
How this compares
$6,959 in reported general payments places this provider in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 62 | $75,797 |
| RexultiBrexpiprazole | 38 | $74,625 |
| TrintellixVortioxetine Hydrobromide | 62 | $41,870 |
| Lamotrigine ErLamotrigine | 24 | $6,264 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 94 | $5,440 |
| Aripiprazole | 74 | $4,603 |
| Olanzapine | 67 | $1,921 |
| Buspirone Hcl | 135 | $1,840 |
| Bupropion XlBupropion Hcl | 101 | $1,299 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 27 | $1,262 |
| Quetiapine Fumarate | 104 | $1,254 |
| Doxepin Hcl | 38 | $1,187 |
| Olanzapine OdtOlanzapine | 12 | $1,168 |
| Ziprasidone Hcl | 29 | $1,121 |
| Fluoxetine Hcl | 105 | $1,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $583 | $75,79762 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $589 | $74,62538 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $389 | $41,87062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Elizabethtown
- Amanda MedleyElizabethtown$14K
- Jason DunnElizabethtown$11K
- Donald BlackburnElizabethtown$8K
- Sandra AubreyElizabethtown$7K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.